Research Article
Statistical Genomic Approach Identifies Association between FSHR Polymorphisms and Polycystic Ovary Morphology in Women with Polycystic Ovary Syndrome
Table 3
FSHR polymorphisms versus endocrine parameters in PCO patients.
| | | rs2268361 | | value | | rs2349415 | | value | | GG | GA | AA | CC | CT | TT |
| Case number | 106 | 205 | 73 | — | 202 | 156 | 26 | — | Age, year | 26.82 ± 3.95 | 27.45 ± 3.67 | 26.92 ± 4.52 | 0.33 | 27.19 ± 4. 16 | 26.96 ± 3.70 | 28.42 ± 3.15 | 0.21 | BMI, kg/m2 | 22.67 ± 4.75 | 22.90 ± 4.91 | 22.89 ± 3.98 | 0.92 | 22.81 ± 4.32 | 22.83 ± 5.12 | 23.00 ± 5.02 | 0.98 | WHR | 0.82 ± 0.08 | 0.83 ± 0.08 | 0.82 ± 0.07 | 0.82 | 0.82 ± 0.08 | 0.82 ± 0.07 | 0.82 ± 0.06 | 0.99 | Acne score | 1 (0–4) | 0 (0–5) | 0 (0–5) | 0.07 | 0 (0–4) | 0 (0–5) | 1 (0–4) | 0.63 | mF-G score | 5 (0–27) | 4 (0–35) | 3.5 (0–22) | 0.12 | 4 (0–35) | 4 (0–29) | 5.5 (0–16) | 0.33 | CHOL, mmol/L | 4.89 ± 0.82 | 4.99 ± 0.88 | 5.04 ± 0.90 | 0.54 | 4.93 ± 0.89 | 5.01 ± 0.88 | 5.03 ± 0.69 | 0.69 | TG, mmol/L | 1.30 ± 0.82 | 1.37 ± 0.91 | 1.22 ± 0.62 | 0.44 | 1.27 ± 0.89 | 1.27 ± 0.89 | 1.39 ± 0.76 | 0.45 | HDL-C, mmol/L | 1.60 ± 0.42 | 1.58 ± 0.46 | 1.51 ± 0.42 | 0.42 | 1.53 ± 0.40 | 1.62 ± 0.49 | 1.56 ± 0.41 | 0.21 | LDL-C, mmol/L | 2.81 ± 0.76 | 2.93 ± 0.84 | 3.04 ± 0.84 | 0.21 | 2.94 ± 0.84 | 2.86 ± 0.83 | 3.02 ± 0.59 | 0.58 | HOMA-IR | 2.09 ± 1.78 | 2.45 ± 2.10 | 2.39 ± 1.91 | 0.30 | 2.29 ± 1.75 | 2.44 ± 2.32 | 2.12 ± 1.38 | 0.66 | HOMA-ISI | 0.03 ± 0.02 | 0.03 ± 0.03 | 0.03 ± 0.02 | 0.82 | 0.03 ± 0.03 | 0.03 ± 0.02 | 0.03 ± 0.03 | 0.97 | HOMA-β% | 120.98 ± 156.82 | 135.70 ± 121.63 | 136.74 ± 111.78 | 0.61 | 125.02 ± 125.61 | 140.06 ± 137.64 | 135.56 ± 122.83 | 0.56 | FSH, IU/L | 6.58 ± 2.16 | 6.65 ± 2.50 | 5.72 ± 1.90 | 0.02 | 6.31 ± 2.12 | 6.58 ± 2.65 | 6.82 ± 1.63 | 0.41 | LH, IU/L | 11.65 ± 7.47 | 10.62 ± 6.73 | 10.42 ± 7.02 | 0.41 | 10.40 ± 6.62 | 11.26 ± 7.17 | 12.11 ± 8.48 | 0.36 | PRL, ng/mL | 16.05 ± 10.02 | 17.46 ± 12.46 | 15.04 ± 8.60 | 0.28 | 16.11 ± 10.44 | 16.88 ± 11.78 | 19.19 ± 13.29 | 0.45 | E2, ng/L | 72.88 ± 67.09 | 63.21 ± 63.91 | 92.84 ± 106.84 | 0.03 | 71.16 ± 76.83 | 71.96 ± 64.84 | 70.74 ± 115.86 | 0.99 | TT, nmol/L | 2.43 ± 1.24 | 2.41 ± 1.46 | 2.35 ± 0.94 | 0.92 | 2.36 ± 1.07 | 2.50 ± 1.61 | 2.09 ± 0.98 | 0.29 | A2, ng/mL | 5.03 ± 2.20 | 5.37 ± 2.62 | 5.07 ± 2.42 | 0.71 | 5.18 ± 2.29 | 5.43 ± 2.80 | 4.34 ± 1.50 | 0.39 | FT, pg/mL | 4.36 ± 5.62 | 5.04 ± 6.34 | 4.11 ± 3.49 | 0.41 | 4.76 ± 5.81 | 4.78 ± 5.81 | 2.92 ± 2.04 | 0.37 | DHEA-S, ng/mL | 2124.35 ± 1049.61 | 2178.40 ± 989.35 | 2158.74 ± 1009.01 | 0.91 | 2165.36 ± 924.47 | 2206.65 ± 1103.63 | 1774.35 ± 1013.97 | 0.18 | E1, pg/mL | 124.49 ± 71.96 | 126.03 ± 98.92 | 87.97 ± 57.90 | 0.29 | 119.74 ± 73.46 | 116.73 ± 102.42 | 105.78 ± 72.28 | 0.91 | SHBG, nmol/L | 76.09 ± 72.20 | 61.64 ± 51.50 | 53.97 ± 33.05 | 0.03 | 56.46 ± 35.97 | 73.13 ± 73.71 | 71.07 ± 48.71 | 0.02 | 17-OHP, ng/mL | 1.25 ± 1.04 | 1.26 ± 0.81 | 1.33 ± 0.76 | 0.82 | 1.33 ± 0.99 | 1.22 ± 0.74 | 1.13 ± 0.50 | 0.44 |
|
|
Significant difference was in bold. PCO: polycystic ovary; BMI: body mass index; WHR: waist-hip ratio; mF-G score: modified Ferriman-Gallwey score; CHOL: cholesterol; TG: triglycerides; HDL-C: high-density lipoprotein-cholesterol; LDL-C: low-density lipoprotein-cholesterol; HOMA-IR/HOMA-ISI/HOMA-β%: homeostatic model assessment for insulin resistance/insulin sensitivity/β; FSH: follicle stimulating hormone; LH: luteinizing hormone; PRL: prolactin; E2: estradiol; TT: total testosterone; A2: androstenedione; FT: free testosterone; DHEA-S: dehydroepiandrosterone sulfate; E1: estrone; SHBG: sex hormone binding globulin; 17-OHP: 17-hydroxyprogesterone.
|